Orchestra BioMed

Yahoo Finance • last month

Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout

Results from long-term follow up of patients treated with atrioventricular interval modulation (“AVIM”) therapy show blood pressure-lowering effects are sustained for years after activation, reversible with no observed rebound hypertension... Full story

Yahoo Finance • 2 months ago

Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology

Data from acute and chronic pressure-volume loop studies support the mechanism of action and show a favorable impact of AVIM therapy on blood pressure and cardiovascular hemodynamicsAVIM therapy drove statistically significant reductions i... Full story

Yahoo Finance • 2 months ago

AVIM therapy shows promise for patients with diastolic dysfunction

NEW HOPE, Pa. - Orchestra BioMed Holdings, Inc. (Nasdaq:OBIO), a medical technology company with a market capitalization of $143.5 million and impressive gross profit margins of 92.7%, announced Thursday that a new study published in JACC:... Full story

Yahoo Finance • 2 months ago

Orchestra BioMed GAAP EPS of -$0.50, revenue of $0.84M

* Orchestra BioMed press release [https://seekingalpha.com/pr/20197531-orchestra-biomed-reports-second-quarter-2025-financial-results-and-highlights-recent-business] (NASDAQ:OBIO [https://seekingalpha.com/symbol/OBIO]): Q2 GAAP EPS of -$... Full story

Yahoo Finance • 2 months ago

Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

Secured over $111 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by over $71 million in committed capital from Medtronic and LigandAchieved m... Full story

Yahoo Finance • 2 months ago

Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility

FDA-approved protocol update significantly expands patient eligibility criteria for the BACKBEAT global pivotal study (“BACKBEAT study”), resulting in an estimated more than 24-fold increase in the potentially eligible patient pool as comp... Full story

Yahoo Finance • 2 months ago

Orchestra BioMed director Hochman buys $55,000 in OBIO stock

Director David P. Hochman of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has recently purchased 20,000 shares of the company’s common stock at $2.75 per share, according to a Form 4 filing with the Securities and Exchange Commission. The... Full story

Yahoo Finance • 2 months ago

Orchestra BioMed Announces Proposed Public Offering

NEW HOPE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing part... Full story

Yahoo Finance • 2 months ago

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

• Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra’s AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to invest $10 million in an equity private p... Full story

Yahoo Finance • 4 months ago

Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025

Presentation underscores unique potential for atrioventricular interval modulation (“AVIM”) therapy to manage blood pressure in older, high-risk patients who have indicators of diastolic dysfunction and progression to heart failure with pr... Full story

Yahoo Finance • 5 months ago

Orchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

Secured ten new fully-issued patents related to hypertension treatment during last 12 months, bringing global issued patent estate total for this condition to 120 patentsPatent estate covering atrioventricular interval modulation (“AVIM”)... Full story

Yahoo Finance • 6 months ago

Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting

FDA recently granted Breakthrough Device Designation to AVIM therapy for use in patients with uncontrolled hypertension at increased cardiovascular riskHRS Satellite Symposium will feature leading experts in electrophysiology, hypertension... Full story

Yahoo Finance • 6 months ago

Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy

Breakthrough Device Designation (“BDD”) applies to an estimated U.S. population of over 7.7 million patients with uncontrolled hypertension and increased cardiovascular riskBDD also encompasses pacemaker-indicated patients with uncontrolle... Full story

Yahoo Finance • 6 months ago

Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward... Full story

Yahoo Finance • 8 months ago

Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board

The BACKBEAT global pivotal study is currently enrolling patients to evaluate the efficacy and safety of atrioventricular interval modulation (“AVIM”) therapy for patients who have uncontrolled hypertension and a pacemaker indicationA glob... Full story

Yahoo Finance • 8 months ago

Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference

Late-breaking oral presentation features echocardiographic data analysis showing favorable impact of AVIM therapy on MODERATO II study patients with diastolic dysfunction, a key component in the development of heart failureHypertension is... Full story

Yahoo Finance • 8 months ago

Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

Medical device industry veteran brings over three decades of expertise in M&A, as well as structured research and development (“R&D”) collaborations aligned with Orchestra BioMed’s partnership-enabled business model Mr. Cleary previously s... Full story

Yahoo Finance • 2 years ago

Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update

U.S. FDA granted Investigational Device Exemption (“IDE”) approval to initiate the BACKBEAT pivotal study evaluating AVIM therapy (BackBeat CNT) in hypertensive pacemaker patients BACKBEAT pivotal study on track to start enrollment before... Full story

Yahoo Finance • 2 years ago

Orchestra BioMed to Present at Upcoming Investor Conferences

NEW HOPE, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing par... Full story

Yahoo Finance • 2 years ago

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Hypertension is the most common comorbidity in the pacemaker population, affecting over 70% of patients or approximately 750,000 people annually worldwideMedtronic plc and Orchestra BioMed have an exclusive strategic collaboration for glob... Full story